Abstract: The present invention relates to an immunogenic polypeptide comprising a multitude of human papillomavirus (HPV) L2 N-terminal peptides corresponding to amino acids 20 to 50 of the L2 polypeptide of HPV16, wherein said HPV L2 N-terminal peptides are L2 N-terminal peptides from at least two different HPV genotypes. The present invention also relates to said immunogenic polypeptide for use in medicine and for use in vaccination against HPV infection. Moreover, the present invention relates to a polynucleotide encoding the immunogenic polypeptide and to a host cell comprising the same. Moreover, the present invention relates to kits, methods, and uses related to the immunogenic polypeptide of the invention.

Abstract: The present invention relates to a method for differentiating in a subject with HR-HPV between a severe form of HR-HPV infection and a mild form of HR-HPV infection. It further is concerned with a composition comprising a probe oligonucleotide mixture, a device, and a kit for use in conjunction with the method of the invention.

Abstract: The present invention relates to a parvovirus for the treatment of mesenchymal tumors, preferably malignant bone tumors such as localized and metastasized bone tumors, in particular osteosarcoma and Ewing's sarcoma. A preferred parvovirus includes a replication competent parvovirus H-1PV.

Abstract: The present invention relates to the field of diagnostic tests and diagnostic tools. Specifically, contemplated is to a method for diagnosing cancer in a sample of a subject suspected to suffer from cancer comprising contacting the sample with an antibody which specifically binds to the epitope characterized by SEQ ID NO 1 on a BRAF polypeptide under conditions which allow for binding of said antibody to the epitope and determining binding of the antibody to the epitope, whereby cancer is diagnosed. Further contemplated are antibodies which specifically bind to the epitope characterized by SEQ ID NO 1 on a BRAF polypeptide and a device or kit comprising such antibodies.

Abstract: Described is a parvovirus, in particular a H-IPV, that can be genetically retargeted through modification of its capsid, which is useful in cancer therapy.

Abstract: Described are (a) parvovirus variants capable of propagating and spreading through human tumor cells which is obtainable by serially passaging a rodent parvovirus as starting strain in semi-permissive human tumor cells, and (b) parvovirus variants capable of propagating and spreading through human tumor cells characterized by particular amino acid deletions and/or substitutions, e.g. a deletion of several amino acids in the C-terminus of NS1/middle exon of NS2. A pharmaceutical composition containing such parvoviruses as well as their use for the treatment of cancer, preferably a glioblastoma, is also described.

Abstract: The present invention discloses an ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens for use in the prophylaxis and treatment of patients with a reduced T cell activity in order to prevent or treat growth of EBV infected B cells.

Abstract: The invention relates to a transmission electron microscope equipped with a 2k?2k pixel area Slow Scan Cooled Charge Coupled Device Camera connected to an image processing software for generating an image of a sample. A segmentation of gold particles in the sample is achieved by the separation from specimen structure and background noise. An identification and classification of particle types is carried out according to the shape and size of the detected particles or particle pairs and finally, the gold particle distribution is visualized by the generation of false color overlay images as well as the indication of the numbers in the image.

Abstract: The invention relates to a method for inhibiting CD95-independent apoptosis, comprising the following steps: (a) blocking the bonding of HIV-1 gp120 on receptors CD4 and/or CXCR4 or of a factor competing for this bonding, and/or (b) inhibiting the signal path induced by the bonding of (a). The invention also relates to a system for identifying substances which can be utilized for inhibiting CD95-independent apoptosis.

Abstract: The invention relates to dendrimers comprising an initiator core with at least two functional groups and at least two saccharides, a process for preparing sch dendrimers as well as uses thereof.

Abstract: This invention relates to a DNA encoding a peptide of a papilloma virus major capsid protein. Furthermore, this invention deals with a papilloma virus genome containing such a DNA. In addition, this invention concerns proteins encoded by the papilloma virus genome and virus-like particles as well as antibodies directed thereagainst and the use thereof and the use thereof in diagnosis, treatment and vaccination.

Abstract: The present invention relates to a DNA construct containing a cDNA sequence for human poly(ADP-ribose)-polymerase, cell lines containing the DNA construct, and a process for identifying DNA-damaging substances by means of these cell lines which overexpress poly(ADP-ribose)-polymerase.

Abstract: The antenna system of the invention is insulated on the outside and when inserted in a dissipative medium has a fixed complex resistance. When the antenna is supplied with HF energy through a coaxial cable, only that area of the medium immediately around the antenna is heated. The area surrounding the insulated HF feed line is not heated, or such heating is negligible, since, owing to the fixed complex resistance of the antenna in the medium, any return of energy along the feed line is prevented. The antenna system of the invention is suitable for use in the tumor-therapy field as a hyperthermic microwave applicator for limited local heating of cancerous tissue.